BIOADAPTIVES INC

For the period ended Dec 31, 2023. Filed Apr 10, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 10, 2024

BDPTStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Deficit

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

Series A · Series B · Additional
Preferred stock · Preferred stock · Common stock · paid-in · Accumulated
Shares · Amount · Shares · Amount · Shares · Amount · capital · Deficit · Total
Balance, December 31, 2021	1,600,000	$160	-	$	-	50,819,780	$5,082	$5,557,828	$(6,656,109)	$(1,093,039)
Common stock issued for conversion of debt	-	-	-		-	201,734,985	20,173	501,506	-	521,679
Debts forgiveness - related party	-	-	-		-	-	-	10,000	-	10,000
Warrant issued for Patent’s acquisition	-	-	-		-	-	-	5,429	-	5,429
Net loss for the period	-	-	-		-	-	-	-	(895,570)	(895,570)
Balance, December 31, 2022	1,600,000	$160	-	$	-	252,554,765	$25,255	$6,074,763	$(7,551,679)	$(1,451,501)
Series A preferred stock issued for license fee	1,250,000	125	-		-	-	-	22,500	-	22,625
Series B preferred stock issued for license fee	-	-	1,500,000		150	-	-	17,850	-	18,000
Series B preferred stock issued for settlement of debt - related party	-	-	750,000		75	-	-	16,425	-	16,500
Common stock issued for cash	-	-	-		-	200,000,000	20,000	158,100	-	178,100
Common stock issued for conversion of debt	-	-	-		-	443,205,460	44,321	237,790	-	282,111
Net loss for the period	-	-	-		-	-	-	-	(712,466)	(712,466)
Balance, December 31, 2023	2,850,000	$285	2,250,000		$225	895,760,225	$89,576	$6,527,428	$(8,264,145)	$(1,646,631)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.